Terns Pharmaceuticals, Inc. TERN
We take great care to ensure that the data presented and summarized in this overview for Terns Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TERN
View all-
Soleus Capital Management, L.P. Greenwich, CT8.17MShares$46.3 Million1.87% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.56MShares$42.9 Million0.65% of portfolio
-
Morgan Stanley New York, NY7.11MShares$40.3 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA6.9MShares$39.1 Million5.17% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.58MShares$31.6 Million0.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.15MShares$23.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.12MShares$23.4 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.91MShares$22.2 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY3.84MShares$21.8 Million0.07% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL2.63MShares$14.9 Million0.0% of portfolio
Latest Institutional Activity in TERN
Top Purchases
Top Sells
About TERN
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Insider Transactions at TERN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 01
2025
|
Emil Kuriakose Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
853
-1.6%
|
$3,412
$4.27 P/Share
|
|
Jun 27
2025
|
Andrew Gengos Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+18.33%
|
$30,000
$3.93 P/Share
|
|
Jun 25
2025
|
Amy L. Burroughs Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
23,314
+33.12%
|
$69,942
$3.87 P/Share
|
|
Jun 16
2025
|
Andrew Gengos Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+25.0%
|
$15,000
$3.95 P/Share
|
|
Jun 13
2025
|
Andrew Gengos Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+41.67%
|
$30,000
$3.74 P/Share
|
|
Apr 01
2025
|
Emil Kuriakose Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
952
-1.75%
|
$1,904
$2.49 P/Share
|
|
Jan 06
2025
|
Jill M. Quigley |
SELL
Open market or private sale
|
Direct |
8,760
-100.0%
|
$43,800
$5.79 P/Share
|
|
Jan 06
2025
|
Mark J. Vignola Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,059
-10.81%
|
$45,295
$5.8 P/Share
|
|
Jan 02
2025
|
Jill M. Quigley |
SELL
Open market or private sale
|
Direct |
6,240
-41.6%
|
$31,200
$5.72 P/Share
|
|
Jan 02
2025
|
Mark J. Vignola Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,129
-8.84%
|
$40,645
$5.72 P/Share
|
|
Jan 02
2025
|
Emil Kuriakose Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,481
-7.63%
|
$22,405
$5.71 P/Share
|
|
Dec 05
2024
|
Amy L. Burroughs Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
15,450
+44.72%
|
$108,150
$7.15 P/Share
|
|
Nov 30
2024
|
Amy L. Burroughs Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
510
+2.53%
|
$2,550
$5.11 P/Share
|
|
Nov 30
2024
|
Melita Sun Jung Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
2,250
+50.0%
|
$11,250
$5.11 P/Share
|
|
Sep 12
2024
|
Lu Hongbo |
BUY
Open market or private purchase
|
Indirect |
476,190
+43.75%
|
$4,761,900
$10.5 P/Share
|
|
Sep 10
2024
|
Mark J. Vignola Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-9.81%
|
$110,000
$11.0 P/Share
|
|
Sep 10
2024
|
Mark J. Vignola Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+8.93%
|
$50,000
$5.36 P/Share
|
|
Sep 09
2024
|
Jill M. Quigley |
SELL
Open market or private sale
|
Direct |
17,235
-53.47%
|
$172,350
$10.0 P/Share
|
|
Sep 09
2024
|
Jill M. Quigley |
BUY
Exercise of conversion of derivative security
|
Direct |
17,235
+34.84%
|
$17,235
$1.82 P/Share
|
|
Aug 02
2024
|
Jill M. Quigley |
SELL
Open market or private sale
|
Direct |
8,857
-37.13%
|
$61,999
$7.5 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 543K shares |
|---|---|
| Exercise of conversion of derivative security | 27.2K shares |
| Open market or private sale | 80.7K shares |
|---|